The degradation of PNP by <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crc</i>Y, and DLL-Δ<i>crcZ</i>. Tekijä Shuang Li (146392)

Aiheet:

The growth of <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crcY</i>, and DLL-Δ<i>crcZ</i> on LB medium. Tekijä Shuang Li (146392)

Aiheet:

Aggregated results for reported benefits and harms, stratified by leaflets and booklets. Tekijä Maren Dreier (628959)

“…<p>The figure indicates whether a leaflet contains <u>any</u> information on the benefits of CRC screening a) in general or specifically for b) colonoscopy or c) the FOBT, and whether it contains any information on the d) general and e) specific harms of colonoscopy. To be rated positive for harms, it was not sufficient if the only information about possible harms referred to pain, stating incorrectly that there is no pain involved.…”

Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. Tekijä Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. Tekijä Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. Tekijä Diana M. Hendrickx (1507435)

Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. Tekijä Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. Tekijä Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. Tekijä Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. Tekijä Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. Tekijä Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... Tekijä Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. Tekijä Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. Tekijä Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... Tekijä Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. Tekijä Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determin... Tekijä Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB. Tekijä Diana M. Hendrickx (1507435)

Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study. Tekijä Diana M. Hendrickx (1507435)

Aerosol Capture for Coupling to Microfluidics: A Miniaturized Low-Cost Device for Size-Resolved Particle Collection Tekijä Yao Xiao (227567)